{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:15:42Z","timestamp":1790720142981,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multi-drug resistant bacterial infections are an increasing threat to the efficacy of currently used antibiotics worldwide. When designing rational antibiotic therapies, a comprehensive understanding of the complex interplay between the antibiotic and the bacteria, the pharmacodynamics (PD), is a prerequisite. The most often-used metric to assess the PD of antibiotics is the minimum inhibitory concentration (MIC). However, the MIC is a summary metric based on a single timepoint observation and does not reflect bacterial dynamics. This work aims to summarize published antibiotic PD metrics and their respective applications to encourage researchers and healthcare professionals to use the most informative metrics for their specific objectives. This review is structured based on the data needed to derive the PD metrics, e.g. single timepoint or longitudinal data. In addition, this review highlights how pharmacometric modelling can maximize the knowledge obtained from the reported metrics and how modelling can serve as an important approach to aid the design of rational antibiotic treatments, aiming to maximize their benefit\u2013risk ratio.<\/jats:p>","DOI":"10.1093\/jac\/dkaf374","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:27:13Z","timestamp":1762882033000},"source":"Crossref","is-referenced-by-count":4,"title":["Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2418-9500","authenticated-orcid":false,"given":"Malin","family":"Andersson","sequence":"first","affiliation":[{"name":"Dept. of Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX , Berlin\/Potsdam ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3157-814X","authenticated-orcid":false,"given":"Nicole","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Dept. of Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX , Berlin\/Potsdam ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-8514","authenticated-orcid":false,"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[{"name":"Dept. of Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX , Berlin\/Potsdam ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4840-5704","authenticated-orcid":false,"given":"Linda B S","family":"Aulin","sequence":"additional","affiliation":[{"name":"Dept. of Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2026011413274997900_dkaf374-B1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global Burden of Bacterial Antimicrobial Resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026011413274997900_dkaf374-B2","author":"WHO"},{"key":"2026011413274997900_dkaf374-B3","author":"WHO"},{"key":"2026011413274997900_dkaf374-B4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41579-021-00578-9","article-title":"Optimizing antimicrobial use: challenges, advances and opportunities","volume":"19","author":"Rawson","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"2026011413274997900_dkaf374-B5","author":"EMA"},{"key":"2026011413274997900_dkaf374-B6","author":"EUCAST"},{"key":"2026011413274997900_dkaf374-B7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s42003-020-01127-5","article-title":"Robust estimation of bacterial cell count from optical density","volume":"3","author":"Beal","year":"2020","journal-title":"Commun Biol"},{"key":"2026011413274997900_dkaf374-B9","author":"ISO 20776-1"},{"key":"2026011413274997900_dkaf374-B10","author":"CLSI"},{"key":"2026011413274997900_dkaf374-B11","author":"CLSI"},{"key":"2026011413274997900_dkaf374-B12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1469-0691.1998.tb00061.x","article-title":"Methods for the determination of susceptibility of bacteria to antimicrobial agents. Terminology","volume":"4","author":"EUCAST","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"2026011413274997900_dkaf374-B13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/139.5.599","article-title":"Minimal antibiotic concentrations of aminoglycosides and \u03b2-lactam antibiotics for some Gram-negative bacilli and Gram-positive cocci","volume":"139","author":"Lorian","year":"1979","journal-title":"J Infect Dis"},{"key":"2026011413274997900_dkaf374-B14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/clinids\/1.5.821","article-title":"Range of antibacterial activity of antibiotics at subminimal inhibitory concentrations: the ratio of minimal inhibitory concentration to minimal antibiotic concentration","volume":"1","author":"Ezrow","year":"1979","journal-title":"Rev Infect Dis"},{"key":"2026011413274997900_dkaf374-B15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","article-title":"Mechanisms and clinical relevance of bacterial heteroresistance","volume":"17","author":"Andersson","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2026011413274997900_dkaf374-B16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026011413274997900_dkaf374-B17","first-page":"301","volume-title":"Annual Reports in Medicinal Chemistry","author":"Swinney","year":"2011"},{"key":"2026011413274997900_dkaf374-B18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/antibiotics10060615","article-title":"Novel pharmacokinetic\/pharmacodynamic parameters quantify the exposure\u2013effect relationship of levofloxacin against fluoroquinolone-resistant Escherichia coli","volume":"10","author":"Seeger","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026011413274997900_dkaf374-B19","doi-asserted-by":"publisher","first-page":"e02307-18","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","article-title":"Distinguishing between resistance, tolerance and persistence to antibiotic treatment","volume":"14","author":"Brauner","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"2026011413274997900_dkaf374-B22","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.bpj.2017.05.014","article-title":"An experimental framework for quantifying bacterial tolerance","volume":"112","author":"Brauner","year":"2017","journal-title":"Biophys J"},{"key":"2026011413274997900_dkaf374-B23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0196-4399(91)90030-Y","article-title":"The postantibiotic effect","volume":"13","author":"Craig","year":"1991","journal-title":"Clin Microbiol Newsl"},{"key":"2026011413274997900_dkaf374-B24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jac\/31.6.881","article-title":"Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem","volume":"31","author":"Odenholt-Tornqvist","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/106002809102500210","article-title":"The postantibiotic effect: a review of in vitro and in vivo data","volume":"25","author":"Zhanel","year":"1991","journal-title":"DICP"},{"key":"2026011413274997900_dkaf374-B26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0021-9258(18)65573-5","article-title":"Antagonists of nucleic acid derivatives: VIII. Synergism in combinations of biochemically related antimetabolites","volume":"208","author":"Elion","year":"1954","journal-title":"J Biol Chem"},{"key":"2026011413274997900_dkaf374-B27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0732-8893(02)00473-X","article-title":"Comparison of methods of interpretation of checkerboard synergy testing","volume":"44","author":"Bonapace","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026011413274997900_dkaf374-B28","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1128\/AAC.06113-11","article-title":"Novel modeling framework to guide design of optimal dosing strategies for \u03b2-lactamase inhibitors","volume":"56","author":"Bhagunde","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B29","article-title":"The \u03b2-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic\/pharmacodynamic relationship of piperacillin\/tazobactam for dosing optimisation","author":"Andersson","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B30","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/AAC.41.6.1281","article-title":"Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration\u2013time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model","volume":"41","author":"Firsov","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.40.3.734","article-title":"Predictors of effect of ampicillin-sulbactam against TEM-1 \u03b2-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC","volume":"40","author":"Firsov","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B32","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1128\/AAC.01585-08","article-title":"Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia","volume":"53","author":"Harigaya","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B33","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/AAC.48.10.3670-3676.2004","article-title":"Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens","volume":"48","author":"Regoes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00003088-200544020-00005","article-title":"Pharmacokinetic\/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration","volume":"44","author":"Mouton","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2026011413274997900_dkaf374-B35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/00044011-199611040-00006","article-title":"Dosage regimens of antibacterials: implications of a pharmacokinetic\/pharmacodynamic model","volume":"11","author":"Bouvier d'Yvoire","year":"1996","journal-title":"Clin Drug Investig"},{"key":"2026011413274997900_dkaf374-B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jac\/dkp434","article-title":"In vitro pharmacodynamic models to determine the effect of antibacterial drugs","volume":"65","author":"Gloede","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC","volume":"48","author":"Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026011413274997900_dkaf374-B40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2026011413274997900_dkaf374-B41","doi-asserted-by":"publisher","first-page":"770518","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026011413274997900_dkaf374-B42","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/AAC.42.4.744","article-title":"Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics","volume":"42","author":"den Hollander","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274997900_dkaf374-B43","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","article-title":"Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs","volume":"65","author":"Nielsen","year":"2013","journal-title":"Pharmacol Rev"},{"key":"2026011413274997900_dkaf374-B44","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/antibiotics11080986","article-title":"Pharmacokinetic\/pharmacodynamic modeling and application in antibacterial and antifungal pharmacotherapy: a narrative review","volume":"11","author":"Pereira","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026011413274997900_dkaf374-B45","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bja.2024.11.044","article-title":"Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokinetics","volume":"134","author":"Bindellini","year":"2025","journal-title":"Br J Anaesth"},{"key":"2026011413274997900_dkaf374-B46","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.cmi.2020.04.009","article-title":"Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy","volume":"26","author":"Ehmann","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026011413274997900_dkaf374-B47","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/jac\/dkab146","article-title":"Quantification of persister formation of Escherichia coli leveraging electronic cell counting and semi-mechanistic pharmacokinetic\/pharmacodynamic modelling","volume":"76","author":"Seeger","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274997900_dkaf374-B48","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1128\/aem.56.6.1875-1881.1990","article-title":"Modeling of the bacterial growth curve","volume":"56","author":"Zwietering","year":"1990","journal-title":"Appl Environ Microbiol"},{"key":"2026011413274997900_dkaf374-B49","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/js9801337","article-title":"Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics","volume":"87","author":"Yano","year":"1998","journal-title":"J Pharm Sci"},{"key":"2026011413274997900_dkaf374-B50","doi-asserted-by":"publisher","first-page":"106616","DOI":"10.1016\/j.ijantimicag.2022.106616","article-title":"Pharmacokinetic\/pharmacodynamic models for time courses of antibiotic effects","volume":"60","author":"Minichmayr","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413274997900_dkaf374-B51","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41467-017-01929-y","article-title":"A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions","volume":"8","author":"Wicha","year":"2017","journal-title":"Nat Commun"},{"key":"2026011413274997900_dkaf374-B52","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026011413274997900_dkaf374-B53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2049","article-title":"Perspectives on model-informed precision dosing in the digital health era: challenges, opportunities, and recommendations","volume":"109","author":"Kluwe","year":"2021","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf374\/65272203\/dkaf374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf374\/65272203\/dkaf374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:54Z","timestamp":1768415274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf374\/8321199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf374","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,11]]},"article-number":"dkaf374"}}